Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fuma... — RxCUI 1306298
RxNorm drug concept · Semantic branded drug
RxCUI 1306298
Semantic branded drug · SBD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1306298
Official nameCobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Stribild]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asStribild (cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG (equivalent to tenofovir disoproxil 245 MG)) Oral Tablet; Stribild 150 MG / 150 MG / 200 MG / 300 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)2,282 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Emtricitabine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Emtricitabine doesn't cure HIV, but it's an important part of keeping the virus under control. It works by blocking an enzyme HIV needs to make copies of itself. When it's used alo...
- What exactly does emtricitabine do — does it cure HIV?
- Please don't stop without talking to your doctor first. If you also have hepatitis B, stopping emtricitabine can trigger a sudden, severe flare of hepatitis B — sometimes serious e...
- Can I stop taking emtricitabine if I feel fine or if I also have hepatitis B?
🕸️ Concept Web — How Cobicistat 150 MG / elvitegravir 150 MG / emtric... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet [Stribild]
RxCUI 1306298 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 6
The active substance itself — no strength, form, or brand attached yet.
-
Cobicistat
1306284IN -
Elvitegravir
1306286IN -
Emtricitabine
276237IN -
Tenofovir disoproxil
300195IN -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
1306291MIN -
Tenofovir disoproxil fumarate
322248PIN
-
Cobicistat
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Stribild
1306293BN
-
Stribild
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Tablet
1306290SCDF -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Oral Tablet
2646705SCDFP -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Product
1306288SCDG -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Pill
1306289SCDG -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Oral Product
2662487SCDGP -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Pill
2661409SCDGP -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Tablet [Stribild]
1306295SBDF -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Oral Tablet [Stribild]
2657975SBDFP - +5 more in this family
-
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Tablet
-
Clinical & branded drugs 6
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
1306292SCD -
Cobicistat 150 MG
1306285SCDC -
Elvitegravir 150 MG
1306287SCDC -
Emtricitabine 200 MG
406016SCDC -
Tenofovir disoproxil fumarate 300 MG
393334SCDC -
Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG [Stribild]
1306294SBDC
-
Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
Showing up to 8 concepts per family — 21 of 26 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG Oral Tablet
SCD · 1306292 -
Cobicistat 150 MG
SCDC · 1306285 -
Elvitegravir 150 MG
SCDC · 1306287 -
Emtricitabine 200 MG
SCDC · 406016 -
Tenofovir disoproxil fumarate 300 MG
SCDC · 393334 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Tablet
SCDF · 1306290 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Oral Tablet
SCDFP · 2646705 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Product
SCDG · 1306288 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Pill
SCDG · 1306289 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Oral Product
SCDGP · 2662487
Brand-Name Concepts
-
Cobicistat 150 MG / elvitegravir 150 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG [Stribild]
SBDC · 1306294 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil Oral Tablet [Stribild]
SBDF · 1306295 -
Cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil fumarate Oral Tablet [Stribild]
SBDFP · 2657975 -
Stribild Oral Product
SBDG · 1306296 -
Stribild Pill
SBDG · 1306297 -
Stribild
BN · 1306293
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 1306298 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 61958-1201-01 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1201-1) | Stribild | Gilead Sciences, Inc. | 2012-08-27 |
Observed labelers:
Gilead Sciences, Inc. (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$149.6310
Range $149.6310–$149.6310
· middle 50% $149.6310–$149.6310
· 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.